FREQUENCY OF ASPIRIN RESISTANCE IN PATIENTS WITH TYPE 1 AND 2 DIABETES MELLITUS AND ITS ASSOCIATION WITH METABOLIC PARAMETERS

Deniz Gokalp, Alpaslan Tuzcu, Ster Irmak, Mithat Bahceci, Ozlem Demirpence

2021, Vol: 7, Issue: 3

7/3Current Issue Online First Archive Aims and Scope Abstracting & Indexing Most Accessed Articles Most Downloaded Articles Most Cited Articles

Required files to be uploaded

Copyright Transfer Form

« Previous Article

Original Research

Int J Surg Med. 2016; 2(3): 122-126

doi: 10.5455/ijsm.aspirin-resistance-diabetes

FREQUENCY OF ASPIRIN RESISTANCE IN PATIENTS WITH TYPE 1 AND 2 DIABETES MELLITUS AND ITS ASSOCIATION WITH METABOLIC PARAMETERS

Deniz Gokalp, Alpaslan Tuzcu, Ster Irmak, Mithat Bahceci, Ozlem Demirpence.

Cited by (1)

Abstract
Objectives: In the present study, we aimed to determine the prevalence of aspirin resistance in patients with Type 1 and 2 diabetes and to study its association with metabolic parameters.
Methods: Aspirin resistance of patients (n=158) with Type 2 Diabetes Mellitus (DM) who presented to the center after 7 days of regular aspirin use were compared to age-mathced (55±19) healthy controls (n=164). Similarly, aspirin resistance of patients (n=30) diagnosed with Type 1 DM were compared to age-matched (27±7) healthy subjects (n=41) as the control group. Platelet Function Analyzer (PFA)-100 was used to evaluate the efficacy of aspirin.
Results: Aspirin resistance was identified in 72 of 158 patients with Type 2 DM (45.6%) and in 47 of 164 healthy controls (28.6%) (p=0.001). Aspirin resistance had a prevalence of 50% in patients with Type 1 DM and was significantly higher compared to the control group of 41 healthy subjects (12.2%) (p=0.001). No correlations were noted between aspirin resistance and sex, smoking, HbA1c, hypertension and aspirin dose. There was a significant relation between aspirin resistance and LDL-cholesterol in patients with Type 2 DM (p=0.020).
Conclusion: Patients with Type 1 and Type 2 DM had a higher frequency of aspirin resistance than the control group. Therefore, treatment choices including administering higher doses of aspirin or using other antiplatelet agents such as clopidogrel should be considered to prevent thrombocytic events in diabetes mellitus.

Key words: Type 1 Diabetes, Type 2 Diabetes, Aspirin resistance.

	ARTICLE TOOLS
	Abstract
	PDF Fulltext
	How to cite this article
	Citation Tools
	Related Records
	Articles by Deniz Gokalp Articles by Alpaslan Tuzcu Articles by Ster Irmak Articles by Mithat Bahceci Articles by Ozlem Demirpence
	on Google
	on Google Scholar

REFERENCES

1. Cubbon RM, Wheatcroft SB, Grant PJ, Gale CP, Barth JH, Sapsford RJ, et al. Temporal trends in mortality of patients with diabetes mellitus suffering acute myocardial infarction: a comparison of over 3000 patients between 1995 and 2003. Eur Heart J. 2007;28:540-5. [DOI via Crossref] [Pubmed]

2. Buse JB, Ginsberg HN, Bakris GL, Clark NG, Costa F, Eckel R, et al. For the American Heart Association and Amer-ican Diabetes Association. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement fromtheAmerican Heart Association and theAmer-ican Diabetes Association. Circulation. 2007;115:114-26. [DOI via Crossref] [Pubmed]

3. Rao GH. Influence of anti-platelet drugs on pla-telet-vessel wall interactions. Prostaglandins, Leukotri-enes and Medicine, 1987, 30, 133-145. [DOI via Crossref]

4. Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S.Aspirin-resistant throm-boxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation, 2002, 105, 1650-1655. [DOI via Crossref] [Pubmed]

5. Winocour PD. Platelet turnover in advanced diabetes. Eur J Clin Invest. 1994;24:34-7. [DOI via Crossref] [Pubmed]

6. Antithrombotic Trialists' Collaboration (2002) Collaborative meta-analysis of randomised trials of antitrombosit therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324:71-86. [DOI via Crossref]

7. Sacco M, Pellegrini F, Roncaglioni MC, Avanzini F, Tognoni G, Nicolucci A (2003) Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial. Diabetes Care 26:3264-3272. [DOI via Crossref] [Pubmed]

8. Watala C, Golanski J, Pluta J, Boncler M, Rozalski M, Luzak B. et al (2004) Reduced sensitivity of trombosits from type 2 diabetic patients to acetylsalicylic acid (aspirin)Â— its relation to metabolic control. Thromb Res 113:101-113. [DOI via Crossref] [Pubmed]

9. Mehta SS, Silver RJ, Aaronson A, Abrahamson M, Goldfme AB (2006) Comparison of aspirin resistance in type 1 versus type 2 diabetes mellitus. Am J Cardiol 97:567-570. [DOI via Crossref] [Pubmed]

10. Gum PA, Kottke-Marchant K, Poggio ED, Gurm H, Welsh PA, Brooks L.et al (2001) Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 88:230-235. [DOI via Crossref]

11. Watala C, Pluta J, Golanski J, Rozalski M, Czyz M, Trojanowski Z, et al (2005) Increased protein glycation in diabetes mellitus is associated with decreased aspirin-mediated protein acetylation and reduced sensitivity of blood trombosits to aspirin. J Mol Med 83:148-158. [DOI via Crossref] [Pubmed]

12. Fateh-Moghadam S, Plockinger U, Cabeza N, Htun P, Reuter T, Ersel S.et al (2005) Prevalence of aspirin resistance in patients with type 2 diabetes. Acta Diabetol 42:99-103. [DOI via Crossref] [Pubmed]

13. Takahashi S, Ushida M, Komine R, Shimizu A, Uchida T, Ishihara H, et al. Increased basal platelet activity, plasma adiponectin levels, and diabetes mellitus are associated with poor platelet responsiveness to in vitro effect of aspirin. Thromb Res 2007; 119: 517-24. [DOI via Crossref] [Pubmed]

14. Early Treatment Diabetic Retinopathy Study Investigators (1992) Aspirin effects on mortality and morbidity in patients with diabetes mellitus. ETDRS report 14. JAMA 268:1292-1300. [DOI via Crossref] [Pubmed]

15. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK.et al Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST elevation. N Engl J Med 2001; 345:494-502 [DOI via Crossref] [Pubmed]

16. Steinhubl SR, Berger PB, Mann JT, Fry ET, DeLago A, Wilmer C. et al. Early and sustained dual oral antitrombosit therapy following percutaneous coronary intervention: a randomised controlled trial. JAMA 2002; 288: 2411-20. [DOI via Crossref] [Pubmed]

17. Sabatine MS, Cannon CP, Gibson CM, LÃ³pez-SendÃ³n JL, Montalescot G, Theroux P.et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005; 352: 1179-89. [DOI via Crossref] [Pubmed]

18. Bellavance A. Efficacy of ticlopidine and aspirin for prevention of reversible cerebrovascular ischemic events. The Ticlopidine Aspirin Stroke Study. Stroke 1993;24: 1452-7. [DOI via Crossref] [Pubmed]

19. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996;348:1329-39. [DOI via Crossref]

20. Peters RJ, Mehta SR, Fox KA, Zhao F, Lewis BS, Kopecky SL, et al. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation 2003;108:1682-7. [DOI via Crossref] [Pubmed]

This Article Cited By the following articles

Effects of aspirin in combination with EPA and DHA on HDL-C cholesterol and ApoA1 exchange in individuals with type 2 diabetes mellitus Prostaglandins, Leukotrienes and Essential Fatty Acids (PLEFA) 2017; 126(): 25.	1

How to Cite this Article

Pubmed Style

Deniz Gokalp, Alpaslan Tuzcu, Ster Irmak, Mithat Bahceci, Ozlem Demirpence. FREQUENCY OF ASPIRIN RESISTANCE IN PATIENTS WITH TYPE 1 AND 2 DIABETES MELLITUS AND ITS ASSOCIATION WITH METABOLIC PARAMETERS. Int J Surg Med. 2016; 2(3): 122-126. doi:10.5455/ijsm.aspirin-resistance-diabetes

Web Style

Deniz Gokalp, Alpaslan Tuzcu, Ster Irmak, Mithat Bahceci, Ozlem Demirpence. FREQUENCY OF ASPIRIN RESISTANCE IN PATIENTS WITH TYPE 1 AND 2 DIABETES MELLITUS AND ITS ASSOCIATION WITH METABOLIC PARAMETERS. http://www.ejos.org/?mno=229387 [Access: November 03, 2020]. doi:10.5455/ijsm.aspirin-resistance-diabetes

AMA (American Medical Association) Style

Deniz Gokalp, Alpaslan Tuzcu, Ster Irmak, Mithat Bahceci, Ozlem Demirpence. FREQUENCY OF ASPIRIN RESISTANCE IN PATIENTS WITH TYPE 1 AND 2 DIABETES MELLITUS AND ITS ASSOCIATION WITH METABOLIC PARAMETERS. Int J Surg Med. 2016; 2(3): 122-126. doi:10.5455/ijsm.aspirin-resistance-diabetes

Vancouver/ICMJE Style

Deniz Gokalp, Alpaslan Tuzcu, Ster Irmak, Mithat Bahceci, Ozlem Demirpence. FREQUENCY OF ASPIRIN RESISTANCE IN PATIENTS WITH TYPE 1 AND 2 DIABETES MELLITUS AND ITS ASSOCIATION WITH METABOLIC PARAMETERS. Int J Surg Med. (2016), [cited November 03, 2020]; 2(3): 122-126. doi:10.5455/ijsm.aspirin-resistance-diabetes

Harvard Style

Deniz Gokalp, Alpaslan Tuzcu, Ster Irmak, Mithat Bahceci, Ozlem Demirpence (2016) FREQUENCY OF ASPIRIN RESISTANCE IN PATIENTS WITH TYPE 1 AND 2 DIABETES MELLITUS AND ITS ASSOCIATION WITH METABOLIC PARAMETERS. Int J Surg Med, 2 (3), 122-126. doi:10.5455/ijsm.aspirin-resistance-diabetes

Turabian Style

Deniz Gokalp, Alpaslan Tuzcu, Ster Irmak, Mithat Bahceci, Ozlem Demirpence. 2016. FREQUENCY OF ASPIRIN RESISTANCE IN PATIENTS WITH TYPE 1 AND 2 DIABETES MELLITUS AND ITS ASSOCIATION WITH METABOLIC PARAMETERS. International Journal of Surgery and Medicine, 2 (3), 122-126. doi:10.5455/ijsm.aspirin-resistance-diabetes

Chicago Style

Deniz Gokalp, Alpaslan Tuzcu, Ster Irmak, Mithat Bahceci, Ozlem Demirpence. "FREQUENCY OF ASPIRIN RESISTANCE IN PATIENTS WITH TYPE 1 AND 2 DIABETES MELLITUS AND ITS ASSOCIATION WITH METABOLIC PARAMETERS." International Journal of Surgery and Medicine 2 (2016), 122-126. doi:10.5455/ijsm.aspirin-resistance-diabetes

MLA (The Modern Language Association) Style

Deniz Gokalp, Alpaslan Tuzcu, Ster Irmak, Mithat Bahceci, Ozlem Demirpence. "FREQUENCY OF ASPIRIN RESISTANCE IN PATIENTS WITH TYPE 1 AND 2 DIABETES MELLITUS AND ITS ASSOCIATION WITH METABOLIC PARAMETERS." International Journal of Surgery and Medicine 2.3 (2016), 122-126. Print. doi:10.5455/ijsm.aspirin-resistance-diabetes

APA (American Psychological Association) Style

Deniz Gokalp, Alpaslan Tuzcu, Ster Irmak, Mithat Bahceci, Ozlem Demirpence (2016) FREQUENCY OF ASPIRIN RESISTANCE IN PATIENTS WITH TYPE 1 AND 2 DIABETES MELLITUS AND ITS ASSOCIATION WITH METABOLIC PARAMETERS. International Journal of Surgery and Medicine, 2 (3), 122-126. doi:10.5455/ijsm.aspirin-resistance-diabetes

Author Login Reviewer Login About Publisher Editorial Policies Peer Review Policy Editorial & Peer Review Process Author's Rights and Obligations Publication Ethics and Publication Malpractice Statement Conflict of Interest Policy Plagiarism Policy Protection of Research Participants (Statement On Human And Animal Rights) Privacy Policy Publication Ethics and Publication Malpractice Statement Corrections, Retractions & Expressions of Concern Self-Archiving Policies Statement of Informed Consent Advertising Policy Terms of Use License Information



Copyright © 2021 International Journal of Surgery and Medicine All Rights Reserved. Subject to change without notice from or liability to International Journal of Surgery and Medicine. For best results, please use Internet Explorer or Google Chrome	Contact Information Any correspondence, queries or additional requests for information on the manuscript submission process should be sent to the International Journal of Medical Reviews and Case Reports editorial office as follows: Bulgarian Association of Young Surgeons (BAYS); National Center of Public Health and Analyses (NCPHA), floor 2, office № 31, Sofia 1431, Bulgaria. inkov@journalmedica.com Financial department is managed by International Sci Ink Press. It is a company registered in Bulgaria with registered no. 205414288 and registered address at 57 Antim I str., Vazrazhdane, Sofia, 1303, Bulgaria.

Contact Information

How to cite this article